More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints

 
• By Sten Stovall
Carcinoma
Roche has 8 Phase III lung cancer studies underway evaluating Tecentriq alone or in combination • Source: Shutterstock

More from Immuno-oncology

More from Anticancer